Papers
Research literature with structured metadata.
Trials
Registered studies by status, phase, and compound.
Topics
Indications and themes psychedelics are researched for.
Compounds
Evidence across molecules with rich data.
Countries
Regulation, access, and research activity by region.
Stakeholders
Organizations shaping the space across research, policy, and funding.
People
Investigators, clinicians, and authors with mapped output.
Courses
Training programs and certifications across modalities.
Events
Conferences, workshops, and convenings by date and focus.
Results
Compare outcome data across trials and publications.
Research recaps
Monthly evidence summaries with key takeaways.
Map of research
Landscape view of trials, compounds, and outcomes.
Newsletter
Weekly or daily updates on trials, publications, analysis, and more.
Research Groups
Worldwide map of psychedelic research centres by region.
Road to Access
Science, regulation, and economics on the path to patient access.
Research Network
Interactive co-authorship map of psychedelic researchers.
Top papers
Find needles in the haystack of psychedelic research per topic.
This secondary analysis (n=82) of a Phase III RCT of MDMA-assisted therapy found significant improvements in both uncompassionate self-responding and compassionate self-responding across all six Self-Compassion Scale subscales, most with large effect sizes. Changes in self-compassion fully mediated the reductions in PTSD severity and depressive symptoms observed with MDMA-AT versus placebo plus therapy, though no significant effects were seen for alcohol or substance use outcomes.
This survey (n=68) of researchers and clinicians involved in MDMA-assisted therapy (MDMA-AT) examines opinions on clinical practices, training, and regulation. The study finds broad support for training standardization and highlights challenges in the national (European) approval process. Experts emphasize the importance of science-informed policy, active regulatory involvement, and international cooperation to integrate MDMA-AT into the European mental healthcare system, particularly for treating PTSD.
This systematic review & meta-analysis (2024; s=6; n=221) of randomised control trials (RCTs) on ketamine interventions for PTSD finds a small advantage for ketamine over control conditions in reducing PTSD symptoms at 24 hours post-initial infusion, but bias and heterogeneity pose concerns, indicating that blind penetration and the placebo effect might contribute to reported therapeutic effects.
This analysis of a clinical trial (n=22) examines the role of therapeutic alliance in MDMA-assisted psychotherapy (MDMA-AP) for treating chronic PTSD. It reports that after controlling for baseline PTSD severity, a strong therapeutic alliance at the mid and late stages of treatment (sessions 4 and 9) significantly predicts lower clinician-assessed and self-reported PTSD severity post-treatment.
This survey study (n=121) explored the co-occurrence of PTSD in patients with a substance use disorder (SUD). It was found that SUD patients with PTSD were more likely to use MDMA than those without PTSD and MDMA use was associated with avoidance symptoms. The authors conclude that MDMA use might reflect an attempt to self-medicate to deal with avoidance symptoms however, it may also be the case that MDMA use led to more severe avoidance symptoms.
This open-label study (n=12, 6 couples) describes the safety, tolerability, and efficacy of MDMA in combination with cognitive-behavioral conjoint therapy (CBCT) where one half of the couple was battling with PTSD.